About
Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support. Its products are aimed at addressing insomnia, problems related to the central nervous system, and neurodegenerative diseases. The company's first approved drug is Circadin, a timed-release melatonin for insomnia. Circadin is commercially available in Europe, the AsiaPacific region, and the Middle East. The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for Slenyto, a pediatric prolonged-release melatonin-coated tablet formulation for the treatment of children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome who suffer from insomnia.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Neurim Pharmaceuticals founded?
- Neurim Pharmaceuticals was founded in June 1991.
- What is Neurim Pharmaceuticals' primary focus?
- Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support, addressing insomnia, central nervous system problems, and neurodegenerative diseases.
- What was Neurim Pharmaceuticals' first approved drug and where is it available?
- Neurim Pharmaceuticals' first approved drug is Circadin, a timed-release melatonin for insomnia, commercially available in Europe, the Asia-Pacific region, and the Middle East.
- What is Slenyto and for what condition has it received a positive opinion from the European Medicines Agency?
- Slenyto is a pediatric prolonged-release melatonin-coated tablet formulation. In July 2018, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Slenyto for the treatment of insomnia in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome.
- When did Health Canada approve Slenyto for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome?
- In September 2025, Health Canada granted marketing authorization for Slenyto, an extended-release melatonin formulation, as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome.
- Which company was granted marketing rights for PedPRM in Spain by Neurim Pharmaceuticals?
- In March 2017, Neurim Pharmaceuticals granted Exeltis marketing rights for Paediatric Prolonged-Release Melatonin (PedPRM) in Spain.
- When did Neurim Pharmaceuticals report success in an Alzheimer's disease trial?
- In June 2014, Neurim Pharmaceuticals reported success in an Alzheimer's disease trial.
- Who was an investor in Neurim Pharmaceuticals' Seed round in January 2000?
- Prof. Nava & Yehuda Zisapel were investors in Neurim Pharmaceuticals' Seed round in January 2000.